In ocular surgery, with penetrating incisions, we inevitably still face postoperative inflammation and pain. Now, a novel potent corticosteroid formulation could help improve that aspect of cataract surgery as well, with enhanced penetration and an easier-to-follow dosing regimen.
Rho kinase inhibitors—the newest drugs introduced for treating glaucoma—"get to the heart of the matter” by targeting specific glaucomatous abnormalities, such as trabecular meshwork outflow, said Yvonne Ou, MD.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
